Allarity Therapeutics (NASDAQ: ALLR) has announced the appointment of Jeff Ervin as chief financial officer (CFO), succeeding Alexander Epshinsky, who will remain involved during the transition period.
Mr. Ervin brings nearly two decades of executive leadership experience across healthcare, biotech, and other sectors to the role. Most recently, he served as co-chief financial officer at DayDayCook (NYSEM: DDC). He holds an MBA in Finance and Strategy from Vanderbilt University’s Owen Graduate School of Business.
In a statement, Thomas Jensen, CEO of Allarity, commented, “We are pleased to welcome Jeff to the Allarity executive team. His strong track record in public company leadership and financial management aligns well with our mission to accelerate the clinical development of stenoparib. Jeff’s extensive experience will be highly valuable in supporting a sustainable financial strategy and the execution of our expanding clinical trial activities. I would also like to extend my sincere thanks to Alex for his valuable contributions to Allarity and wish him continued success in his future endeavors.”
